Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CLK1 | P49759 | 1/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PKLR | P30613 | 1/20 | 0.51 |
| ▸ | FASN | P49327 | 1/20 | 0.51 |
| ▸ | GABRP | O00591 | 1/20 | 0.50 |
| ▸ | GABRD | O14764 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15712649 | 0.88 | ELANE (0.62) | ELANEMAPTHPGDCLK1CDK5 | |
| Ethoxycarbonyl Group SCHEMBL27664509 | 0.86 | ELANE (0.52) | ELANEMAPTHPGDCLK1CDK5 | |
| SCHEMBL8538289 | 0.84 | TDO2 (0.56) | ELANEMAPTHPGDCLK1CDK5 | |
| SCHEMBL28625731 | 0.83 | CLK1 (0.50) | ELANEMAPTHPGDCLK1CDK5 | |
| SCHEMBL14406226 | 0.81 | ELANE (0.61) | ELANEMAPTPKMPKLRMEN1 | |
| SCHEMBL28132752 | 0.81 | MEN1 (0.60) | ELANEMAPTHPGDCYP19A1FASN | |
| SCHEMBL23649349 | 0.81 | ELANE (0.60) | ELANEMAPTPKMPKLRMEN1 | |
| SCHEMBL29824887 | 0.81 | ELANE (0.60) | ELANEMAPTPKMPKLRMEN1 | |
| SCHEMBL28464644 | 0.80 | ELANE (0.60) | ELANEMAPTHPGDCLK1CDK5 | |
| SCHEMBL13302290 | 0.80 | ELANE (0.54) | ELANEMAPTCLK1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2915804-B1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF AS TNF ALPHA INHIBITORS | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-9624215-B2 | Amine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9624215-B2 | Amine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9624215-B2 | Amine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20150299189-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299189-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299189-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2915804-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014069510-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | 富山化学工業株式会社 (JP) | 2014-05-08 | — | — | WO | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1771169-A1 | METHODS FOR TREATING HEPATITIS C | PTC Therapeutics, Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060223863-A1 | Methods for treating Hepatitis C | KARP GARY M | 2006-10-05 | — | — | US | disclosed |
| US-20060189606-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2006019831-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | ELANE 226/4885MAPT 4416/4885HPGD 1033/4885 |
| US-20150299189-A1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF | HRH4, CLIC4, KRT18 | ELANE 294/4885MAPT 4564/4885HPGD 1430/4885 |
| US-20060189606-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | ELANE 1098/4885MAPT 4477/4885HPGD 3255/4885 |
| US-20070299069-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | ELANE 1098/4885MAPT 4477/4885HPGD 3255/4885 |
| US-20060223863-A1 | Methods for treating Hepatitis C | OAT, HAVCR2, HCCS | ELANE 226/4885MAPT 4416/4885HPGD 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.